Sales of Roche Holding's anti-obesity drug Xenical have risen 90% in New Zealand since it was made available without prescription six months ago, but a women's group says ads for the drug target people who do not need it. A Roche spokesman said the average size of a person taking Xenical has fallen from a body mass index of 36 to 34 since the drug was given OTC status.

Related Summaries